Global Major Depressive Disorder (MDD) Market Size, Status and Forecast 2021-2027

Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person's ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.
The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

Market Analysis and Insights: Global Major Depressive Disorder (MDD) Market
The global Major Depressive Disorder (MDD) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Major Depressive Disorder (MDD) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Major Depressive Disorder (MDD) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Major Depressive Disorder (MDD) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Major Depressive Disorder (MDD) market.

Global Major Depressive Disorder (MDD) Scope and Market Size
Major Depressive Disorder (MDD) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Major Depressive Disorder (MDD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Antidepressant Drugs
SSRIs
SNRIs
Benzodiazepines
Others

Segment by Application
Hospitals
Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
GlaxoSmithKline
Merck
AstraZeneca
Eli Lily
Johnson & Johnson
Forest Laboratories
Sanofi-Aventis
H. Lundbeck